News

The deal will see AstraZeneca acquire exclusive global rights from Heptares to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and

The CMA has issued a statement of objections to these two firms alleging that they have breached the UK and EU competition law. The drug, which is indicated

IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2

The company is focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection. The primary end point of the Phase III trial is to

It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. The launch of biosimilar Rituximab will provide a much needed access to patients

Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the Patent Cooperation Treaty. This U.S. patent

These targeted therapies are being developed at a time when cardiovascular, neurodegenerative and metabolic lifestyle diseases are approaching epidemic stages, and viral and bacterial infectious disease conditions are

DMD is a recessive X-linked form of muscular dystrophy, which results in muscle degeneration, difficulty walking, breathing and ultimately death. Diagnosis typically occurs between the ages of 2

The first license agreement is with the Indiana University Research and Technology Corporation (IURTC) and the second is with the IURTC and the University of Alabama at Birmingham